| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.1 |
| Gross profit | 0.1 | 0.1 |
| Net income | -3.7 | 1.4 |
| EPS (diluted, $ a share) | $-1.16 | $0.60 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -50.2% |
|---|---|
| Gross margin | 83.4% |
10-Q filed with the SEC, NASDAQ: VEEA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Veea Inc.: key numbers
- Share price
- $4.78Close, Nov 16
- Market cap
- $19.5M
- Shares outstanding
- 4.07MLatest SEC cover page
- Sector
- Technology
- Industry
- Services-Computer Integrated Systems DesignSIC 7373
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Veea Inc.
All →Veea Leadership Change
Helder Antunes resigned as a director of Veea Inc. effective October 8, 2026, though he will remain with the company as Executive Vice President and Chief Revenue Officer. Following the resignation, the board reduced its size to five members and appointed director Alan Black to the Compensation Committee.
Veea Leadership Change
Kanishka Roy, an existing director of Veea Inc., has been appointed to serve on the company's Audit Committee effective October 6, 2026. This appointment fills a committee role within the board of directors.
Veea $1.65M Debt Financing with NLabs Inc
Veea Inc. entered into four unsecured demand promissory notes with NLabs Inc, a principal stockholder and affiliate of the CEO, for a total principal amount of $1.65 million. The loans carry a 10% annual interest rate and are due on the earlier of December 31, 2026, or upon demand, with proceeds intended for working capital.
- Value
- $1.65M
- Counterparty
- NLabs Inc
- Term
- through Dec 2026
Veea Signs $10M M&A Deal with NovaGen Group B.V.
Veea Inc. has signed a non-binding term sheet for a proposed business combination with NovaGen Group B.V., a regenerative medicine and longevity company. The merger aims to launch NovaGen Health Networks, a global health platform integrating Veea's edge AI infrastructure with NovaGen's cellular science, supported by a $10 million cornerstone investment from GeoNova Capital.
- Value
- $10M
- Counterparty
- NovaGen Group B.V.